Enhanced anti-angiogenic effects of aprepitant-loaded nanoparticles in human umbilical vein endothelial cells

Recent advancements in cancer therapy have led to the development of novel nanoparticle-based drug delivery systems aimed at enhancing the efficacy of chemotherapeutic agents. This study focuses on evaluating aprepitant-loaded PLGA and Eudragit RS 100 nanoparticles for their potential antiangiogenic...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 14; no. 1; pp. 19837 - 17
Main Authors Kaya-Tilki, Elif, Öztürk, Ahmet Alper, Engür-Öztürk, Selin, Dikmen, Miriş
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 27.08.2024
Nature Publishing Group
Nature Portfolio
Subjects
631/67/1059/153
692/4028/67/2328
Angiogenesis
Angiogenesis Inhibitors - chemistry
Angiogenesis Inhibitors - pharmacology
Anti-angiogenesis
Antiangiogenic agents
Antineoplastic drugs
Aprepitant
Aprepitant - pharmacology
Cancer therapies
Cell migration
Cell Movement - drug effects
Cell Survival - drug effects
Cell viability
Chemotherapy
Cytotoxicity
Drug Carriers - chemistry
Drug delivery
Drug delivery systems
Endothelial cells
Fluorescence microscopy
Gene expression
Human Umbilical Vein Endothelial Cells - drug effects
Humanities and Social Sciences
Humans
HUVEC
Internalization
M2c
multidisciplinary
Nanoparticles
Nanoparticles - chemistry
Particle Size
Polylactic Acid-Polyglycolic Acid Copolymer - chemistry
Polylactide-co-glycolide
Science
Science (multidisciplinary)
THP-1
Umbilical vein
Vascular Endothelial Growth Factor A - metabolism
Vascular endothelial growth factor receptors
Aprepitant
THP-1
HUVEC
Anti-angiogenesis
M2c
Online AccessGet full text
ISSN2045-2322
2045-2322
DOI10.1038/s41598-024-70791-y

Cover

Abstract Recent advancements in cancer therapy have led to the development of novel nanoparticle-based drug delivery systems aimed at enhancing the efficacy of chemotherapeutic agents. This study focuses on evaluating aprepitant-loaded PLGA and Eudragit RS 100 nanoparticles for their potential antiangiogenic effects. Characterization studies revealed that aprepitant-loaded nanoparticles exhibited particle sizes ranging from 208.50 to 238.67 nm, with monodisperse distributions (PDI < 0.7) and stable zeta potentials (between − 5.0 and − 15.0 mV). Encapsulation efficiencies exceeding 99% were achieved, highlighting the efficacy of PLGA and Eudragit RS 100 as carriers for aprepitant. Cellular uptake studies demonstrated enhanced internalization of aprepitant-loaded nanoparticles by HUVEC cells compared to free aprepitant, as confirmed by fluorescence microscopy. Furthermore, cytotoxicity assays revealed significant dose-dependent effects of aprepitant-loaded nanoparticles on HUVEC cell viability, with IC 50 values at 24 h of 11.9 µg/mL for Eudragit RS 100 and 94.3 µg/mL for PLGA formulations. Importantly, these nanoparticles effectively inhibited HUVEC cell migration and invasion induced by M2c supernatant, as evidenced by real-time cell analysis and gene expression studies. Moreover, aprepitant-loaded nanoparticles downregulated VEGFA and VEGFB gene expressions and reduced VEGFR-2 protein levels in HUVEC cells, highlighting their potential as antiangiogenic agents. Overall, this research underscores the promise of nanoparticle-based aprepitant formulations in targeted cancer therapy, offering enhanced therapeutic outcomes through improved drug delivery and efficacy against angiogenesis.
AbstractList Recent advancements in cancer therapy have led to the development of novel nanoparticle-based drug delivery systems aimed at enhancing the efficacy of chemotherapeutic agents. This study focuses on evaluating aprepitant-loaded PLGA and Eudragit RS 100 nanoparticles for their potential antiangiogenic effects. Characterization studies revealed that aprepitant-loaded nanoparticles exhibited particle sizes ranging from 208.50 to 238.67 nm, with monodisperse distributions (PDI < 0.7) and stable zeta potentials (between − 5.0 and − 15.0 mV). Encapsulation efficiencies exceeding 99% were achieved, highlighting the efficacy of PLGA and Eudragit RS 100 as carriers for aprepitant. Cellular uptake studies demonstrated enhanced internalization of aprepitant-loaded nanoparticles by HUVEC cells compared to free aprepitant, as confirmed by fluorescence microscopy. Furthermore, cytotoxicity assays revealed significant dose-dependent effects of aprepitant-loaded nanoparticles on HUVEC cell viability, with IC 50 values at 24 h of 11.9 µg/mL for Eudragit RS 100 and 94.3 µg/mL for PLGA formulations. Importantly, these nanoparticles effectively inhibited HUVEC cell migration and invasion induced by M2c supernatant, as evidenced by real-time cell analysis and gene expression studies. Moreover, aprepitant-loaded nanoparticles downregulated VEGFA and VEGFB gene expressions and reduced VEGFR-2 protein levels in HUVEC cells, highlighting their potential as antiangiogenic agents. Overall, this research underscores the promise of nanoparticle-based aprepitant formulations in targeted cancer therapy, offering enhanced therapeutic outcomes through improved drug delivery and efficacy against angiogenesis.
Recent advancements in cancer therapy have led to the development of novel nanoparticle-based drug delivery systems aimed at enhancing the efficacy of chemotherapeutic agents. This study focuses on evaluating aprepitant-loaded PLGA and Eudragit RS 100 nanoparticles for their potential antiangiogenic effects. Characterization studies revealed that aprepitant-loaded nanoparticles exhibited particle sizes ranging from 208.50 to 238.67 nm, with monodisperse distributions (PDI < 0.7) and stable zeta potentials (between − 5.0 and − 15.0 mV). Encapsulation efficiencies exceeding 99% were achieved, highlighting the efficacy of PLGA and Eudragit RS 100 as carriers for aprepitant. Cellular uptake studies demonstrated enhanced internalization of aprepitant-loaded nanoparticles by HUVEC cells compared to free aprepitant, as confirmed by fluorescence microscopy. Furthermore, cytotoxicity assays revealed significant dose-dependent effects of aprepitant-loaded nanoparticles on HUVEC cell viability, with IC50 values at 24 h of 11.9 µg/mL for Eudragit RS 100 and 94.3 µg/mL for PLGA formulations. Importantly, these nanoparticles effectively inhibited HUVEC cell migration and invasion induced by M2c supernatant, as evidenced by real-time cell analysis and gene expression studies. Moreover, aprepitant-loaded nanoparticles downregulated VEGFA and VEGFB gene expressions and reduced VEGFR-2 protein levels in HUVEC cells, highlighting their potential as antiangiogenic agents. Overall, this research underscores the promise of nanoparticle-based aprepitant formulations in targeted cancer therapy, offering enhanced therapeutic outcomes through improved drug delivery and efficacy against angiogenesis.
Recent advancements in cancer therapy have led to the development of novel nanoparticle-based drug delivery systems aimed at enhancing the efficacy of chemotherapeutic agents. This study focuses on evaluating aprepitant-loaded PLGA and Eudragit RS 100 nanoparticles for their potential antiangiogenic effects. Characterization studies revealed that aprepitant-loaded nanoparticles exhibited particle sizes ranging from 208.50 to 238.67 nm, with monodisperse distributions (PDI < 0.7) and stable zeta potentials (between - 5.0 and - 15.0 mV). Encapsulation efficiencies exceeding 99% were achieved, highlighting the efficacy of PLGA and Eudragit RS 100 as carriers for aprepitant. Cellular uptake studies demonstrated enhanced internalization of aprepitant-loaded nanoparticles by HUVEC cells compared to free aprepitant, as confirmed by fluorescence microscopy. Furthermore, cytotoxicity assays revealed significant dose-dependent effects of aprepitant-loaded nanoparticles on HUVEC cell viability, with IC50 values at 24 h of 11.9 µg/mL for Eudragit RS 100 and 94.3 µg/mL for PLGA formulations. Importantly, these nanoparticles effectively inhibited HUVEC cell migration and invasion induced by M2c supernatant, as evidenced by real-time cell analysis and gene expression studies. Moreover, aprepitant-loaded nanoparticles downregulated VEGFA and VEGFB gene expressions and reduced VEGFR-2 protein levels in HUVEC cells, highlighting their potential as antiangiogenic agents. Overall, this research underscores the promise of nanoparticle-based aprepitant formulations in targeted cancer therapy, offering enhanced therapeutic outcomes through improved drug delivery and efficacy against angiogenesis.Recent advancements in cancer therapy have led to the development of novel nanoparticle-based drug delivery systems aimed at enhancing the efficacy of chemotherapeutic agents. This study focuses on evaluating aprepitant-loaded PLGA and Eudragit RS 100 nanoparticles for their potential antiangiogenic effects. Characterization studies revealed that aprepitant-loaded nanoparticles exhibited particle sizes ranging from 208.50 to 238.67 nm, with monodisperse distributions (PDI < 0.7) and stable zeta potentials (between - 5.0 and - 15.0 mV). Encapsulation efficiencies exceeding 99% were achieved, highlighting the efficacy of PLGA and Eudragit RS 100 as carriers for aprepitant. Cellular uptake studies demonstrated enhanced internalization of aprepitant-loaded nanoparticles by HUVEC cells compared to free aprepitant, as confirmed by fluorescence microscopy. Furthermore, cytotoxicity assays revealed significant dose-dependent effects of aprepitant-loaded nanoparticles on HUVEC cell viability, with IC50 values at 24 h of 11.9 µg/mL for Eudragit RS 100 and 94.3 µg/mL for PLGA formulations. Importantly, these nanoparticles effectively inhibited HUVEC cell migration and invasion induced by M2c supernatant, as evidenced by real-time cell analysis and gene expression studies. Moreover, aprepitant-loaded nanoparticles downregulated VEGFA and VEGFB gene expressions and reduced VEGFR-2 protein levels in HUVEC cells, highlighting their potential as antiangiogenic agents. Overall, this research underscores the promise of nanoparticle-based aprepitant formulations in targeted cancer therapy, offering enhanced therapeutic outcomes through improved drug delivery and efficacy against angiogenesis.
Abstract Recent advancements in cancer therapy have led to the development of novel nanoparticle-based drug delivery systems aimed at enhancing the efficacy of chemotherapeutic agents. This study focuses on evaluating aprepitant-loaded PLGA and Eudragit RS 100 nanoparticles for their potential antiangiogenic effects. Characterization studies revealed that aprepitant-loaded nanoparticles exhibited particle sizes ranging from 208.50 to 238.67 nm, with monodisperse distributions (PDI < 0.7) and stable zeta potentials (between − 5.0 and − 15.0 mV). Encapsulation efficiencies exceeding 99% were achieved, highlighting the efficacy of PLGA and Eudragit RS 100 as carriers for aprepitant. Cellular uptake studies demonstrated enhanced internalization of aprepitant-loaded nanoparticles by HUVEC cells compared to free aprepitant, as confirmed by fluorescence microscopy. Furthermore, cytotoxicity assays revealed significant dose-dependent effects of aprepitant-loaded nanoparticles on HUVEC cell viability, with IC50 values at 24 h of 11.9 µg/mL for Eudragit RS 100 and 94.3 µg/mL for PLGA formulations. Importantly, these nanoparticles effectively inhibited HUVEC cell migration and invasion induced by M2c supernatant, as evidenced by real-time cell analysis and gene expression studies. Moreover, aprepitant-loaded nanoparticles downregulated VEGFA and VEGFB gene expressions and reduced VEGFR-2 protein levels in HUVEC cells, highlighting their potential as antiangiogenic agents. Overall, this research underscores the promise of nanoparticle-based aprepitant formulations in targeted cancer therapy, offering enhanced therapeutic outcomes through improved drug delivery and efficacy against angiogenesis.
Recent advancements in cancer therapy have led to the development of novel nanoparticle-based drug delivery systems aimed at enhancing the efficacy of chemotherapeutic agents. This study focuses on evaluating aprepitant-loaded PLGA and Eudragit RS 100 nanoparticles for their potential antiangiogenic effects. Characterization studies revealed that aprepitant-loaded nanoparticles exhibited particle sizes ranging from 208.50 to 238.67 nm, with monodisperse distributions (PDI < 0.7) and stable zeta potentials (between - 5.0 and - 15.0 mV). Encapsulation efficiencies exceeding 99% were achieved, highlighting the efficacy of PLGA and Eudragit RS 100 as carriers for aprepitant. Cellular uptake studies demonstrated enhanced internalization of aprepitant-loaded nanoparticles by HUVEC cells compared to free aprepitant, as confirmed by fluorescence microscopy. Furthermore, cytotoxicity assays revealed significant dose-dependent effects of aprepitant-loaded nanoparticles on HUVEC cell viability, with IC values at 24 h of 11.9 µg/mL for Eudragit RS 100 and 94.3 µg/mL for PLGA formulations. Importantly, these nanoparticles effectively inhibited HUVEC cell migration and invasion induced by M2c supernatant, as evidenced by real-time cell analysis and gene expression studies. Moreover, aprepitant-loaded nanoparticles downregulated VEGFA and VEGFB gene expressions and reduced VEGFR-2 protein levels in HUVEC cells, highlighting their potential as antiangiogenic agents. Overall, this research underscores the promise of nanoparticle-based aprepitant formulations in targeted cancer therapy, offering enhanced therapeutic outcomes through improved drug delivery and efficacy against angiogenesis.
ArticleNumber 19837
Author Engür-Öztürk, Selin
Dikmen, Miriş
Öztürk, Ahmet Alper
Kaya-Tilki, Elif
Author_xml – sequence: 1
  givenname: Elif
  surname: Kaya-Tilki
  fullname: Kaya-Tilki, Elif
  email: elif_kaya@anadolu.edu.tr
  organization: Department of Pharmacology, Faculty of Pharmacy, Anadolu University
– sequence: 2
  givenname: Ahmet Alper
  surname: Öztürk
  fullname: Öztürk, Ahmet Alper
  organization: Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University
– sequence: 3
  givenname: Selin
  surname: Engür-Öztürk
  fullname: Engür-Öztürk, Selin
  organization: Department of Pharmacy Services, Tavas Vocational School of Health Services, Pamukkale University
– sequence: 4
  givenname: Miriş
  surname: Dikmen
  fullname: Dikmen, Miriş
  organization: Department of Pharmacology, Faculty of Pharmacy, Anadolu University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39191829$$D View this record in MEDLINE/PubMed
BookMark eNp9kktv1TAQhSNUREvpH2CBIrFhE_AjTuwVQlWBSpVYwN6a2ON7XSX2xU4q3X9f30eh7aLe2Bp_5-hoZt5WJyEGrKr3lHymhMsvuaVCyYawtulJr2izfVWdMdKKhnHGTh69T6uLnG9JOYKplqo31SlXVFHJ1Fk1XYU1BIO2hjD7BsLKxxUGb2p0Ds2c6-hq2CTc-LkQzRjBFjhAiBtIszcj5tqHer1MEOplGvzoDYz1HZYiBhvnNY6-FAyOY35XvXYwZrw43ufV7-9Xfy5_Nje_flxffrtpjGjp3CB2PbQIA-3IILoOjXVIcBAt4aaXYJ0jjGDvpLBGcqYGaTigdbyzDvh5dX1wtRFu9Sb5CdJWR_B6X4hppY_RNW-B9Z1SUqq-FRZByc6gUMoI5oDtvL4evDbLMKE1GOYE4xPTpz_Br_Uq3mlKeauk4sXh09Ehxb8L5llPPu-6AQHjkjUnqpeCtpwU9OMz9DYuKZRO7amOKUL6Qn14HOlfloehFkAeAJNizgmdNmV4s4-7hH7UlOjdCunDCumyQnq_QnpbpOyZ9MH9RRE_iHKBwwrT_9gvqO4BAyrcWQ
CitedBy_id crossref_primary_10_1016_j_jddst_2025_106721
Cites_doi 10.3109/08923973.2015.1122616
10.3390/polym11101632
10.1073/pnas.2023829118
10.3322/caac.20075
10.1007/s10616-021-00498-9
10.1371/journal.pcbi.1007493
10.3389/fonc.2016.00152
10.1038/nature04483
10.3109/03639045.2012.737331
10.1016/j.phrs.2012.10.022
10.1038/s41598-018-36394-0
10.1016/j.jddst.2021.102580
10.1016/j.cellsig.2007.05.013
10.2147/IJN.S132780
10.1016/j.jsps.2011.04.001
10.3390/cancers12092682
10.1039/c2jm31794j
10.4314/tjpr.v18i1.1
10.1177/1087057113499405
10.1038/labinvest.3780013
10.1080/03639045.2020.1755304
10.1042/BJ20110301
10.1007/s10616-014-9692-5
10.1088/1361-6528/ac1098
10.1158/1078-0432.CCR-07-2141
10.1007/s12038-015-9530-8
10.1016/j.jddst.2019.101240
10.1007/s00018-005-5426-3
10.1007/s11033-022-07329-w
10.3389/fimmu.2019.00792
10.1080/03639045.2019.1665061
10.1016/j.phrs.2019.01.013
10.4172/pharmaceutical-sciences.1000200
10.1634/theoncologist.6-suppl_5-32
10.1007/s11051-015-2875-y
10.1016/j.neuroscience.2013.12.027
10.1080/17843286.2017.1302623
10.1016/j.colsurfb.2014.09.002
10.4274/tjps.galenos.2018.34392
10.1208/s12249-013-0044-0
10.1038/srep14273
10.1177/0885328213486705
10.3390/nu9030249
10.1039/c000022a
10.1016/j.jddst.2022.103139
10.3390/ijms19061801
10.1016/j.mimet.2008.03.002
10.1016/S0939-6411(00)00087-4
10.21769/BioProtoc.2646
10.1016/j.jconrel.2008.12.018
10.1007/s10456-017-9552-y
10.2174/1386207323666200325155020
10.18632/oncotarget.5325
10.1002/mnfr.201500407
10.2174/1574892816666211013113841
10.2174/138945011795528796
10.1038/s41565-021-00858-8
10.1089/adt.2020.1014
10.1016/j.joen.2013.11.021
10.1016/j.ijpharm.2023.123136
10.1074/jbc.274.43.31047
10.1016/j.jconrel.2015.11.003
10.12991/jrp.2019.150
10.23893/1307-2080.APS.05627
10.3390/sci1020048
10.1007/s11033-021-06928-3
10.1371/journal.pone.0260633
10.1155/2022/8082608
10.1038/nmeth.f.263
10.35333/jrp.2020.115
ContentType Journal Article
Copyright The Author(s) 2024
2024. The Author(s).
The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2024 2024
Copyright_xml – notice: The Author(s) 2024
– notice: 2024. The Author(s).
– notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2024 2024
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-024-70791-y
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central Database Suite (ProQuest)
Natural Science Collection
ProQuest One Community College
ProQuest Central
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
ProQuest Health & Medical Collection
Medical Database
Science Database (ProQuest)
Biological Science Database (ProQuest)
Proquest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database
MEDLINE - Academic


MEDLINE
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 17
ExternalDocumentID oai_doaj_org_article_34a27699889745dea986ce599c52fa2a
PMC11349893
39191829
10_1038_s41598_024_70791_y
Genre Journal Article
GrantInformation_xml – fundername: Anadolu Üniversitesi
  grantid: 2103S115
  funderid: http://dx.doi.org/10.13039/501100008770
– fundername: Anadolu Üniversitesi
  grantid: 2103S115
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
AARCD
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c541t-ee67a4eab160b566ecdfe0eb5403c78adff020e7f85dc8329b8c3aedf36dfa3
IEDL.DBID M48
ISSN 2045-2322
IngestDate Wed Aug 27 01:25:10 EDT 2025
Thu Aug 21 18:32:05 EDT 2025
Fri Sep 05 10:45:17 EDT 2025
Wed Aug 13 09:50:22 EDT 2025
Wed Feb 19 02:09:46 EST 2025
Tue Jul 01 03:22:50 EDT 2025
Thu Apr 24 23:08:10 EDT 2025
Fri Feb 21 02:40:04 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Aprepitant
THP-1
HUVEC
Anti-angiogenesis
M2c
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c541t-ee67a4eab160b566ecdfe0eb5403c78adff020e7f85dc8329b8c3aedf36dfa3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41598-024-70791-y
PMID 39191829
PQID 3097629007
PQPubID 2041939
PageCount 17
ParticipantIDs doaj_primary_oai_doaj_org_article_34a27699889745dea986ce599c52fa2a
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11349893
proquest_miscellaneous_3097851430
proquest_journals_3097629007
pubmed_primary_39191829
crossref_citationtrail_10_1038_s41598_024_70791_y
crossref_primary_10_1038_s41598_024_70791_y
springer_journals_10_1038_s41598_024_70791_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-08-27
PublicationDateYYYYMMDD 2024-08-27
PublicationDate_xml – month: 08
  year: 2024
  text: 2024-08-27
  day: 27
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2024
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Muñoz, Coveñas, Esteban, Redondo (CR7) 2015; 40
Öztürk, Namlı, Güleç, Görgülü (CR28) 2020; 23
Bardelli (CR51) 2013; 68
Ridhurkar (CR57) 2013; 39
Figueiredo (CR65) 2021; 118
Dikmen, Canturk, Tilki, Engur (CR32) 2017; 79
Yao, Xu, Jin (CR10) 2019; 10
Engür, Dikmen, Öztürk (CR37) 2016; 38
Jiménez-López (CR29) 2019; 141
CR36
Holmes, Roberts, Thomas, Cross (CR76) 2007; 19
Rixe, Fojo (CR3) 2007; 13
Rizwanullah (CR6) 2023; 642
CR30
Müller, Mäder, Gohla (CR41) 2000; 50
Liu, Lin, Qin (CR64) 2010; 10
Giles (CR69) 2001; 6
Öztürk, Yenilmez, Şenel, Kıyan, Güven (CR19) 2020; 46
Schneider (CR50) 2014; 40
Nagarwal, Kant, Singh, Maiti, Pandit (CR15) 2009; 136
Öztürk, Kirimlioğlu (CR43) 2019; 23
Cines (CR72) 1998; 91
Mudshinge, Deore, Patil, Bhalgat (CR14) 2011; 19
Ramjiawan, Griffioen, Duda (CR9) 2017; 20
Akkouch, Zhang, Rouabhia (CR48) 2014; 28
Cerezo, Winterbone, Moyle, Needs, Kroon (CR77) 2015; 59
Rennick, Johnston, Parton (CR46) 2021; 16
Cebe-Suarez, Zehnder-Fjällman, Ballmer-Hofer (CR66) 2006; 63
Rizwanullah, Perwez, Mir, Rizvi, Amin (CR5) 2021; 32
Alper Öztürk, Namlı, Aygül (CR21) 2021; 19
Kriplani, Guarve (CR59) 2022; 17
Muñoz, Coveñas (CR4) 2020; 12
Saraf, Dubey, Dubey, Sharma (CR60) 2021; 64
Harford-Wright, Lewis, Vink, Ghabriel (CR52) 2014; 261
Cerezo, Hornedo-Ortega, Álvarez-Fernández, Troncoso, García-Parrilla (CR61) 2017; 9
Roshan Moniri (CR35) 2015; 67
Engür, Dikmen (CR34) 2017; 72
Ren, Zhou, Wei, Li, Chen (CR13) 2014; 15
Kaya Tilki, Engür Öztürk, Özarda, Cantürk, Dikmen (CR31) 2021; 73
Farzaneh Behelgardi, Zahri, Mashayekhi, Mansouri, Asghari (CR74) 2018; 8
Pettersson (CR73) 2000; 80
Ngamwongsatit, Banada, Panbangred, Bhunia (CR49) 2008; 73
Bernatchez, Soker, Sirois (CR71) 1999; 274
Atri, Guerfali, Laouini (CR11) 2018; 19
Lin (CR47) 2016; 221
Martín-Banderas (CR20) 2014; 123
Öztürk, Martin-Banderas, Cayero-Otero, Yenilmez, Yazan (CR17) 2018; 37
CR56
Ferrara, Kerbel (CR75) 2005; 438
CR55
CR54
Horman, To, Orth (CR63) 2013; 18
Dulak (CR68) 2005; 56
Munoz, Rosso, Covenas (CR8) 2011; 12
Shen, Wu, Liu, Wu (CR44) 2017; 12
Lin (CR12) 2015; 6
Öztürk, Yenilmez, Özarda (CR16) 2019; 11
Şenel, Öztürk (CR18) 2019; 45
Ekinci, Öztürk, Santos-Oliveira, İlem-Özdemir (CR22) 2022; 69
CR27
CR25
CR24
Serkova, Eckhardt (CR2) 2016; 6
Öztürk, Aygül, Şenel (CR23) 2019; 54
Engür-Öztürk, Dikmen (CR39) 2022; 49
Emami, Mohiti, Hamishehkar, Varshosaz (CR40) 2015; 10
Yuan (CR38) 2015; 5
Durán-Lobato, Martín-Banderas, Gonçalves, Fernández-Arévalo, Almeida (CR45) 2015; 17
Cook, Figg (CR67) 2010; 60
Anttila (CR1) 2019; 15
Öztürk (CR26) 2019; 18
Yurtdaş Kırımlıoğlu, Öztürk (CR42) 2020; 17
CR62
Hamidi, Lilja, Ivaska (CR53) 2017; 7
Anirudhan, Sandeep (CR58) 2012; 22
Canturk, Artagan, Dıkmen (CR33) 2016; 25
Koch, Tugues, Li, Gualandi, Claesson-Welsh (CR70) 2011; 437
H Hamidi (70791_CR53) 2017; 7
RR Ramjiawan (70791_CR9) 2017; 20
C Atri (70791_CR11) 2018; 19
AA Öztürk (70791_CR16) 2019; 11
Z Canturk (70791_CR33) 2016; 25
P Ngamwongsatit (70791_CR49) 2008; 73
Y Yao (70791_CR10) 2019; 10
M Roshan Moniri (70791_CR35) 2015; 67
AM Figueiredo (70791_CR65) 2021; 118
M Rizwanullah (70791_CR6) 2023; 642
E Harford-Wright (70791_CR52) 2014; 261
O Rixe (70791_CR3) 2007; 13
SR Mudshinge (70791_CR14) 2011; 19
M Durán-Lobato (70791_CR45) 2015; 17
AA Öztürk (70791_CR28) 2020; 23
S Engür (70791_CR34) 2017; 72
AB Cerezo (70791_CR61) 2017; 9
70791_CR30
M Muñoz (70791_CR7) 2015; 40
A Saraf (70791_CR60) 2021; 64
AB Cerezo (70791_CR77) 2015; 59
S Shen (70791_CR44) 2017; 12
70791_CR36
RC Nagarwal (70791_CR15) 2009; 136
AA Öztürk (70791_CR17) 2018; 37
FJ Giles (70791_CR69) 2001; 6
A Yuan (70791_CR38) 2015; 5
S Engür (70791_CR37) 2016; 38
AA Öztürk (70791_CR43) 2019; 23
J Dulak (70791_CR68) 2005; 56
L Lin (70791_CR12) 2015; 6
KM Cook (70791_CR67) 2010; 60
DN Ridhurkar (70791_CR57) 2013; 39
S Cebe-Suarez (70791_CR66) 2006; 63
PN Bernatchez (70791_CR71) 1999; 274
L Martín-Banderas (70791_CR20) 2014; 123
J Jiménez-López (70791_CR29) 2019; 141
M Dikmen (70791_CR32) 2017; 79
70791_CR62
C Bardelli (70791_CR51) 2013; 68
M Farzaneh Behelgardi (70791_CR74) 2018; 8
SR Horman (70791_CR63) 2013; 18
T Liu (70791_CR64) 2010; 10
G Yurtdaş Kırımlıoğlu (70791_CR42) 2020; 17
70791_CR27
M Munoz (70791_CR8) 2011; 12
70791_CR25
70791_CR24
AA Öztürk (70791_CR26) 2019; 18
A Alper Öztürk (70791_CR21) 2021; 19
A Pettersson (70791_CR73) 2000; 80
E Kaya Tilki (70791_CR31) 2021; 73
A Akkouch (70791_CR48) 2014; 28
R Schneider (70791_CR50) 2014; 40
NJ Serkova (70791_CR2) 2016; 6
T-T Lin (70791_CR47) 2016; 221
K Holmes (70791_CR76) 2007; 19
70791_CR54
DB Cines (70791_CR72) 1998; 91
S Koch (70791_CR70) 2011; 437
AA Öztürk (70791_CR19) 2020; 46
S Engür-Öztürk (70791_CR39) 2022; 49
AA Öztürk (70791_CR23) 2019; 54
JV Anttila (70791_CR1) 2019; 15
J Emami (70791_CR40) 2015; 10
70791_CR56
P Kriplani (70791_CR59) 2022; 17
M Rizwanullah (70791_CR5) 2021; 32
70791_CR55
TS Anirudhan (70791_CR58) 2012; 22
L Ren (70791_CR13) 2014; 15
M Muñoz (70791_CR4) 2020; 12
B Şenel (70791_CR18) 2019; 45
M Ekinci (70791_CR22) 2022; 69
RH Müller (70791_CR41) 2000; 50
N Ferrara (70791_CR75) 2005; 438
JJ Rennick (70791_CR46) 2021; 16
References_xml – volume: 38
  start-page: 87
  year: 2016
  end-page: 97
  ident: CR37
  article-title: Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells
  publication-title: Immunopharmacol. Immunotoxicol.
  doi: 10.3109/08923973.2015.1122616
– volume: 11
  start-page: 1632
  year: 2019
  ident: CR16
  article-title: Clarithromycin-loaded poly (lactic-co-glycolic acid)(PLGA) nanoparticles for oral administration: effect of polymer molecular weight and surface modification with chitosan on formulation, nanoparticle characterization and antibacterial effects
  publication-title: Polymers (Basel)
  doi: 10.3390/polym11101632
– volume: 118
  year: 2021
  ident: CR65
  article-title: Endothelial cell invasion is controlled by dactylopodia
  publication-title: Proc. Natl. Acad. Sci.
  doi: 10.1073/pnas.2023829118
– volume: 60
  start-page: 222
  year: 2010
  end-page: 243
  ident: CR67
  article-title: Angiogenesis inhibitors: Current strategies and future prospects
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.20075
– volume: 73
  start-page: 801
  year: 2021
  end-page: 813
  ident: CR31
  article-title: Investigation of the neuroprotective and neuritogenic effects of halotolerant Penicillium flavigenum-derived sorbicillin-like compounds on PC-12 Adh cells
  publication-title: Cytotechnology
  doi: 10.1007/s10616-021-00498-9
– volume: 56
  start-page: 51
  year: 2005
  end-page: 69
  ident: CR68
  article-title: Nutraceuticals as anti-angiogenic agents: Hopes and reality
  publication-title: J. Physiol. Pharmacol. Suppl.
– volume: 15
  year: 2019
  ident: CR1
  article-title: Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression
  publication-title: PLoS Comput. Biol.
  doi: 10.1371/journal.pcbi.1007493
– volume: 6
  start-page: 152
  year: 2016
  ident: CR2
  article-title: Metabolic imaging to assess treatment response to cytotoxic and cytostatic agents
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2016.00152
– ident: CR54
– volume: 438
  start-page: 967
  year: 2005
  end-page: 974
  ident: CR75
  article-title: Angiogenesis as a therapeutic target
  publication-title: Nature
  doi: 10.1038/nature04483
– volume: 39
  start-page: 1783
  year: 2013
  end-page: 1792
  ident: CR57
  article-title: Inclusion complex of aprepitant with cyclodextrin: Evaluation of physico-chemical and pharmacokinetic properties
  publication-title: Drug Dev. Ind. Pharm.
  doi: 10.3109/03639045.2012.737331
– volume: 91
  start-page: 3527
  year: 1998
  end-page: 3561
  ident: CR72
  article-title: Endothelial cells in physiology and in the pathophysiology of vascular disorders
  publication-title: Blood J. Am. Soc. Hematol.
– volume: 68
  start-page: 24
  year: 2013
  end-page: 30
  ident: CR51
  article-title: Recurrent major depressive disorder: imbalance of neurokinin (NK)-1 and NK-2 receptor expression in monocytes
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2012.10.022
– ident: CR25
– volume: 8
  start-page: 17924
  year: 2018
  ident: CR74
  article-title: A peptide mimicking the binding sites of VEGF-A and VEGF-B inhibits VEGFR-1/-2 driven angiogenesis, tumor growth and metastasis
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-018-36394-0
– volume: 37
  start-page: 1730
  year: 2018
  end-page: 1741
  ident: CR17
  article-title: New approach to hypertension treatment: Carvediol-loaded PLGA nanoparticles, preparation, in vitro characterization and gastrointestinal stability
  publication-title: Lat. Am. J. Pharm.
– volume: 64
  year: 2021
  ident: CR60
  article-title: Enhancement of cytotoxicty of diallyl disulfide toward colon cancer by Eudragit S100/PLGA nanoparticles
  publication-title: J. Drug Deliv. Sci. Technol.
  doi: 10.1016/j.jddst.2021.102580
– volume: 19
  start-page: 2003
  year: 2007
  end-page: 2012
  ident: CR76
  article-title: Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition
  publication-title: Cell Signal
  doi: 10.1016/j.cellsig.2007.05.013
– volume: 12
  start-page: 4085
  year: 2017
  ident: CR44
  article-title: High drug-loading nanomedicines: Progress, current status, and prospects
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S132780
– volume: 19
  start-page: 129
  year: 2011
  end-page: 141
  ident: CR14
  article-title: Nanoparticles: Emerging carriers for drug delivery
  publication-title: Saudi Pharm. J.
  doi: 10.1016/j.jsps.2011.04.001
– volume: 12
  start-page: 2682
  year: 2020
  ident: CR4
  article-title: The neurokinin-1 receptor antagonist aprepitant: An intelligent bullet against cancer?
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12092682
– volume: 22
  start-page: 12888
  year: 2012
  end-page: 12899
  ident: CR58
  article-title: Synthesis, characterization, cellular uptake and cytotoxicity of a multi-functional magnetic nanocomposite for the targeted delivery and controlled release of doxorubicin to cancer cells
  publication-title: J. Mater. Chem.
  doi: 10.1039/c2jm31794j
– volume: 18
  start-page: 1
  year: 2019
  end-page: 11
  ident: CR26
  article-title: Dexketoprofen trometamol-loaded poly-lactic-co-glycolic acid (PLGA) nanoparticles: Preparation, in vitro characterization and cyctotoxity
  publication-title: Trop. J. Pharm. Res.
  doi: 10.4314/tjpr.v18i1.1
– volume: 18
  start-page: 1298
  year: 2013
  end-page: 1308
  ident: CR63
  article-title: An HTS-compatible 3D colony formation assay to identify tumor-specific chemotherapeutics
  publication-title: J. Biomol. Screen
  doi: 10.1177/1087057113499405
– volume: 80
  start-page: 99
  year: 2000
  end-page: 115
  ident: CR73
  article-title: Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor
  publication-title: Lab. Investig.
  doi: 10.1038/labinvest.3780013
– volume: 46
  start-page: 682
  year: 2020
  end-page: 695
  ident: CR19
  article-title: Effect of different molecular weight PLGA on flurbiprofen nanoparticles: Formulation, characterization, cytotoxicity, and in vivo anti-inflammatory effect by using HET-CAM assay
  publication-title: Drug Dev. Ind. Pharm.
  doi: 10.1080/03639045.2020.1755304
– volume: 437
  start-page: 169
  year: 2011
  end-page: 183
  ident: CR70
  article-title: Signal transduction by vascular endothelial growth factor receptors
  publication-title: Biochem. J.
  doi: 10.1042/BJ20110301
– ident: CR36
– volume: 67
  start-page: 379
  year: 2015
  end-page: 386
  ident: CR35
  article-title: Dynamic assessment of cell viability, proliferation and migration using real time cell analyzer system (RTCA)
  publication-title: Cytotechnology
  doi: 10.1007/s10616-014-9692-5
– volume: 32
  year: 2021
  ident: CR5
  article-title: Exemestane encapsulated polymer-lipid hybrid nanoparticles for improved efficacy against breast cancer: Optimization, in vitro characterization and cell culture studies
  publication-title: Nanotechnology
  doi: 10.1088/1361-6528/ac1098
– volume: 13
  start-page: 7280
  year: 2007
  end-page: 7287
  ident: CR3
  article-title: Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-07-2141
– volume: 40
  start-page: 441
  year: 2015
  end-page: 463
  ident: CR7
  article-title: The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs
  publication-title: J. Biosci.
  doi: 10.1007/s12038-015-9530-8
– volume: 54
  year: 2019
  ident: CR23
  article-title: Influence of glyceryl behenate, tripalmitin and stearic acid on the properties of clarithromycin incorporated solid lipid nanoparticles (SLNs): Formulation, characterization, antibacterial activity and cytotoxicity
  publication-title: J. Drug Deliv. Sci. Technol.
  doi: 10.1016/j.jddst.2019.101240
– volume: 10
  start-page: 17
  year: 2015
  ident: CR40
  article-title: Formulation and optimization of solid lipid nanoparticle formulation for pulmonary delivery of budesonide using Taguchi and Box-Behnken design
  publication-title: Res. Pharm. Sci.
– volume: 63
  start-page: 601
  year: 2006
  end-page: 615
  ident: CR66
  article-title: The role of VEGF receptors in angiogenesis; complex partnerships
  publication-title: Cell. Mol. Life Sci.
  doi: 10.1007/s00018-005-5426-3
– volume: 49
  start-page: 4777
  year: 2022
  end-page: 4793
  ident: CR39
  article-title: Proteasome inhibitor immunotherapy for the epithelial to mesenchymal transition: assessing the A549 lung cancer cell microenvironment and the role of M1, M2a and M2c ‘hydrocortisone-polarised’macrophages
  publication-title: Mol. Biol. Rep.
  doi: 10.1007/s11033-022-07329-w
– volume: 10
  start-page: 792
  year: 2019
  ident: CR10
  article-title: Macrophage polarization in physiological and pathological pregnancy
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.00792
– volume: 45
  start-page: 1835
  year: 2019
  end-page: 1848
  ident: CR18
  article-title: New approaches to tumor therapy with siRNA-decorated and chitosan-modified PLGA nanoparticles
  publication-title: Drug Dev. Ind. Pharm.
  doi: 10.1080/03639045.2019.1665061
– volume: 141
  start-page: 451
  year: 2019
  end-page: 465
  ident: CR29
  article-title: A novel nanoformulation of PLGA with high non-ionic surfactant content improves in vitro and in vivo PTX activity against lung cancer
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2019.01.013
– volume: 79
  start-page: 49
  year: 2017
  end-page: 57
  ident: CR32
  article-title: Evaluation of antiangiogenic and antimetastatic Effects of Penicillium chrysogenum Secondary Metabolites
  publication-title: Indian J. Pharm. Sci.
  doi: 10.4172/pharmaceutical-sciences.1000200
– volume: 6
  start-page: 32
  year: 2001
  end-page: 39
  ident: CR69
  article-title: The vascular endothelial growth factor (VEGF) signaling pathway: A therapeutic target in patients with hematologic malignancies
  publication-title: Oncologist
  doi: 10.1634/theoncologist.6-suppl_5-32
– volume: 17
  start-page: 1
  year: 2015
  end-page: 17
  ident: CR45
  article-title: Comparative study of chitosan-and PEG-coated lipid and PLGA nanoparticles as oral delivery systems for cannabinoids
  publication-title: J. Nanoparticle Res.
  doi: 10.1007/s11051-015-2875-y
– volume: 261
  start-page: 85
  year: 2014
  end-page: 94
  ident: CR52
  article-title: Evaluating the role of substance P in the growth of brain tumors
  publication-title: Neuroscience
  doi: 10.1016/j.neuroscience.2013.12.027
– ident: CR30
– volume: 72
  start-page: 391
  year: 2017
  end-page: 398
  ident: CR34
  article-title: The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib
  publication-title: Acta Clin. Belg.
  doi: 10.1080/17843286.2017.1302623
– volume: 123
  start-page: 114
  year: 2014
  end-page: 122
  ident: CR20
  article-title: Engineering of Δ9-tetrahydrocannabinol delivery systems based on surface modified-PLGA nanoplatforms
  publication-title: Colloids Surf. B Biointerfaces
  doi: 10.1016/j.colsurfb.2014.09.002
– volume: 17
  start-page: 27
  year: 2020
  end-page: 35
  ident: CR42
  article-title: Levocetirizine dihydrochloride-loaded chitosan nanoparticles: Formulation and ın vitro evaluation
  publication-title: Turk. J. Pharm. Sci.
  doi: 10.4274/tjps.galenos.2018.34392
– volume: 15
  start-page: 121
  year: 2014
  end-page: 130
  ident: CR13
  article-title: Preparation and pharmacokinetic study of aprepitant–sulfobutyl ether-β-cyclodextrin complex
  publication-title: AAPS PharmSciTech
  doi: 10.1208/s12249-013-0044-0
– volume: 5
  start-page: 14273
  year: 2015
  ident: CR38
  article-title: Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression
  publication-title: Sci. Rep.
  doi: 10.1038/srep14273
– volume: 23
  start-page: 897
  year: 2019
  end-page: 913
  ident: CR43
  article-title: Preparation and in vitro characterization of lamivudine loaded nanoparticles prepared by acid and/or ester terminated PLGA for effective oral anti-retroviral therapy
  publication-title: J. Res. Pharm.
– volume: 28
  start-page: 922
  year: 2014
  end-page: 936
  ident: CR48
  article-title: Engineering bone tissue using human dental pulp stem cells and an osteogenic collagen-hydroxyapatite-poly (l-lactide-co-ɛ-caprolactone) scaffold
  publication-title: J. Biomater. Appl.
  doi: 10.1177/0885328213486705
– volume: 9
  start-page: 249
  year: 2017
  ident: CR61
  article-title: Inhibition of VEGF-induced VEGFR-2 activation and HUVEC migration by melatonin and other bioactive indolic compounds
  publication-title: Nutrients
  doi: 10.3390/nu9030249
– volume: 10
  start-page: 1671
  year: 2010
  end-page: 1677
  ident: CR64
  article-title: Carcinoma-associated fibroblasts promoted tumor spheroid invasion on a microfluidic 3D co-culture device
  publication-title: Lab. Chip
  doi: 10.1039/c000022a
– ident: CR56
– volume: 69
  year: 2022
  ident: CR22
  article-title: The use of Lamivudine-loaded PLGA nanoparticles in the diagnosis of lung cancer: Preparation, characterization, radiolabeling with 99mTc and cell binding
  publication-title: J. Drug Deliv. Sci. Technol.
  doi: 10.1016/j.jddst.2022.103139
– ident: CR27
– volume: 19
  start-page: 1801
  year: 2018
  ident: CR11
  article-title: Role of human macrophage polarization in inflammation during infectious diseases
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms19061801
– volume: 73
  start-page: 211
  year: 2008
  end-page: 215
  ident: CR49
  article-title: WST-1-based cell cytotoxicity assay as a substitute for MTT-based assay for rapid detection of toxigenic Bacillus species using CHO cell line
  publication-title: J. Microbiol. Methods
  doi: 10.1016/j.mimet.2008.03.002
– volume: 50
  start-page: 161
  year: 2000
  end-page: 177
  ident: CR41
  article-title: Solid lipid nanoparticles (SLN) for controlled drug delivery—A review of the state of the art
  publication-title: Eur. J. Pharm. Biopharm.
  doi: 10.1016/S0939-6411(00)00087-4
– volume: 7
  start-page: e2646
  year: 2017
  ident: CR53
  article-title: Using xCELLigence RTCA instrument to measure cell adhesion
  publication-title: Bio. Protoc.
  doi: 10.21769/BioProtoc.2646
– volume: 136
  start-page: 2
  year: 2009
  end-page: 13
  ident: CR15
  article-title: Polymeric nanoparticulate system: A potential approach for ocular drug delivery
  publication-title: J. Controlled Release
  doi: 10.1016/j.jconrel.2008.12.018
– volume: 20
  start-page: 185
  year: 2017
  end-page: 204
  ident: CR9
  article-title: Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
  publication-title: Angiogenesis
  doi: 10.1007/s10456-017-9552-y
– volume: 23
  start-page: 1064
  year: 2020
  end-page: 1079
  ident: CR28
  article-title: Design of lamivudine loaded nanoparticles for oral application by nano spray drying method: A new approach to use an antiretroviral drug for lung cancer treatment
  publication-title: Comb. Chem. High Throughput Screen
  doi: 10.2174/1386207323666200325155020
– volume: 6
  start-page: 34758
  year: 2015
  ident: CR12
  article-title: CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.5325
– volume: 59
  start-page: 2119
  year: 2015
  end-page: 2131
  ident: CR77
  article-title: Molecular structure-function relationship of dietary polyphenols for inhibiting VEGF-induced VEGFR-2 activity
  publication-title: Mol. Nutr. Food Res.
  doi: 10.1002/mnfr.201500407
– volume: 17
  start-page: 92
  year: 2022
  end-page: 101
  ident: CR59
  article-title: Eudragit, a nifty polymer for anticancer preparations: A patent review
  publication-title: Recent Pat. Anticancer Drug Discov.
  doi: 10.2174/1574892816666211013113841
– volume: 12
  start-page: 909
  year: 2011
  end-page: 921
  ident: CR8
  article-title: The NK-1 receptor: A new target in cancer therapy
  publication-title: Curr. Drug Targets
  doi: 10.2174/138945011795528796
– volume: 25
  start-page: 6190
  year: 2016
  end-page: 6197
  ident: CR33
  article-title: Anticancer effects of secondary metabolites of Penicillium chrysogenum var. chrysogenum on colon adenocarcinoma cells
  publication-title: Fresenius Environ. Bull.
– ident: CR55
– volume: 16
  start-page: 266
  year: 2021
  end-page: 276
  ident: CR46
  article-title: Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics
  publication-title: Nat. Nanotechnol.
  doi: 10.1038/s41565-021-00858-8
– volume: 19
  start-page: 156
  year: 2021
  end-page: 175
  ident: CR21
  article-title: Cefaclor monohydrate-loaded colon-targeted nanoparticles for use in COVID-19 dependent coinfections and intestinal symptoms: Formulation, characterization, release kinetics, and antimicrobial activity
  publication-title: Assay Drug Dev. Technol.
  doi: 10.1089/adt.2020.1014
– volume: 40
  start-page: 931
  year: 2014
  end-page: 936
  ident: CR50
  article-title: White mineral trioxide aggregate induces migration and proliferation of stem cells from the apical papilla
  publication-title: J. Endod.
  doi: 10.1016/j.joen.2013.11.021
– ident: CR62
– volume: 642
  year: 2023
  ident: CR6
  article-title: Polymer-lipid hybrid nanoparticles of exemestane for improved oral bioavailability and anti-tumor efficacy: An extensive preclinical investigation
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2023.123136
– ident: CR24
– volume: 274
  start-page: 31047
  year: 1999
  end-page: 31054
  ident: CR71
  article-title: Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.274.43.31047
– volume: 221
  start-page: 62
  year: 2016
  end-page: 70
  ident: CR47
  article-title: Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis
  publication-title: J. Controlled Release
  doi: 10.1016/j.jconrel.2015.11.003
– volume: 72
  start-page: 391
  year: 2017
  ident: 70791_CR34
  publication-title: Acta Clin. Belg.
  doi: 10.1080/17843286.2017.1302623
– volume: 19
  start-page: 156
  year: 2021
  ident: 70791_CR21
  publication-title: Assay Drug Dev. Technol.
  doi: 10.1089/adt.2020.1014
– volume: 10
  start-page: 792
  year: 2019
  ident: 70791_CR10
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.00792
– volume: 5
  start-page: 14273
  year: 2015
  ident: 70791_CR38
  publication-title: Sci. Rep.
  doi: 10.1038/srep14273
– volume: 56
  start-page: 51
  year: 2005
  ident: 70791_CR68
  publication-title: J. Physiol. Pharmacol. Suppl.
– volume: 438
  start-page: 967
  year: 2005
  ident: 70791_CR75
  publication-title: Nature
  doi: 10.1038/nature04483
– volume: 17
  start-page: 92
  year: 2022
  ident: 70791_CR59
  publication-title: Recent Pat. Anticancer Drug Discov.
  doi: 10.2174/1574892816666211013113841
– volume: 60
  start-page: 222
  year: 2010
  ident: 70791_CR67
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.20075
– volume: 37
  start-page: 1730
  year: 2018
  ident: 70791_CR17
  publication-title: Lat. Am. J. Pharm.
– volume: 68
  start-page: 24
  year: 2013
  ident: 70791_CR51
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2012.10.022
– volume: 642
  year: 2023
  ident: 70791_CR6
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2023.123136
– volume: 18
  start-page: 1
  year: 2019
  ident: 70791_CR26
  publication-title: Trop. J. Pharm. Res.
  doi: 10.4314/tjpr.v18i1.1
– volume: 123
  start-page: 114
  year: 2014
  ident: 70791_CR20
  publication-title: Colloids Surf. B Biointerfaces
  doi: 10.1016/j.colsurfb.2014.09.002
– volume: 437
  start-page: 169
  year: 2011
  ident: 70791_CR70
  publication-title: Biochem. J.
  doi: 10.1042/BJ20110301
– ident: 70791_CR25
  doi: 10.12991/jrp.2019.150
– volume: 6
  start-page: 34758
  year: 2015
  ident: 70791_CR12
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.5325
– volume: 19
  start-page: 2003
  year: 2007
  ident: 70791_CR76
  publication-title: Cell Signal
  doi: 10.1016/j.cellsig.2007.05.013
– volume: 6
  start-page: 152
  year: 2016
  ident: 70791_CR2
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2016.00152
– volume: 15
  start-page: 121
  year: 2014
  ident: 70791_CR13
  publication-title: AAPS PharmSciTech
  doi: 10.1208/s12249-013-0044-0
– volume: 69
  year: 2022
  ident: 70791_CR22
  publication-title: J. Drug Deliv. Sci. Technol.
  doi: 10.1016/j.jddst.2022.103139
– volume: 12
  start-page: 909
  year: 2011
  ident: 70791_CR8
  publication-title: Curr. Drug Targets
  doi: 10.2174/138945011795528796
– volume: 7
  start-page: e2646
  year: 2017
  ident: 70791_CR53
  publication-title: Bio. Protoc.
  doi: 10.21769/BioProtoc.2646
– volume: 59
  start-page: 2119
  year: 2015
  ident: 70791_CR77
  publication-title: Mol. Nutr. Food Res.
  doi: 10.1002/mnfr.201500407
– volume: 19
  start-page: 129
  year: 2011
  ident: 70791_CR14
  publication-title: Saudi Pharm. J.
  doi: 10.1016/j.jsps.2011.04.001
– volume: 12
  start-page: 4085
  year: 2017
  ident: 70791_CR44
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S132780
– volume: 221
  start-page: 62
  year: 2016
  ident: 70791_CR47
  publication-title: J. Controlled Release
  doi: 10.1016/j.jconrel.2015.11.003
– volume: 73
  start-page: 801
  year: 2021
  ident: 70791_CR31
  publication-title: Cytotechnology
  doi: 10.1007/s10616-021-00498-9
– volume: 54
  year: 2019
  ident: 70791_CR23
  publication-title: J. Drug Deliv. Sci. Technol.
  doi: 10.1016/j.jddst.2019.101240
– volume: 15
  year: 2019
  ident: 70791_CR1
  publication-title: PLoS Comput. Biol.
  doi: 10.1371/journal.pcbi.1007493
– volume: 22
  start-page: 12888
  year: 2012
  ident: 70791_CR58
  publication-title: J. Mater. Chem.
  doi: 10.1039/c2jm31794j
– volume: 9
  start-page: 249
  year: 2017
  ident: 70791_CR61
  publication-title: Nutrients
  doi: 10.3390/nu9030249
– volume: 45
  start-page: 1835
  year: 2019
  ident: 70791_CR18
  publication-title: Drug Dev. Ind. Pharm.
  doi: 10.1080/03639045.2019.1665061
– volume: 11
  start-page: 1632
  year: 2019
  ident: 70791_CR16
  publication-title: Polymers (Basel)
  doi: 10.3390/polym11101632
– volume: 17
  start-page: 1
  year: 2015
  ident: 70791_CR45
  publication-title: J. Nanoparticle Res.
  doi: 10.1007/s11051-015-2875-y
– volume: 40
  start-page: 441
  year: 2015
  ident: 70791_CR7
  publication-title: J. Biosci.
  doi: 10.1007/s12038-015-9530-8
– volume: 40
  start-page: 931
  year: 2014
  ident: 70791_CR50
  publication-title: J. Endod.
  doi: 10.1016/j.joen.2013.11.021
– volume: 73
  start-page: 211
  year: 2008
  ident: 70791_CR49
  publication-title: J. Microbiol. Methods
  doi: 10.1016/j.mimet.2008.03.002
– volume: 63
  start-page: 601
  year: 2006
  ident: 70791_CR66
  publication-title: Cell. Mol. Life Sci.
  doi: 10.1007/s00018-005-5426-3
– volume: 20
  start-page: 185
  year: 2017
  ident: 70791_CR9
  publication-title: Angiogenesis
  doi: 10.1007/s10456-017-9552-y
– ident: 70791_CR24
  doi: 10.23893/1307-2080.APS.05627
– volume: 17
  start-page: 27
  year: 2020
  ident: 70791_CR42
  publication-title: Turk. J. Pharm. Sci.
  doi: 10.4274/tjps.galenos.2018.34392
– volume: 8
  start-page: 17924
  year: 2018
  ident: 70791_CR74
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-018-36394-0
– volume: 25
  start-page: 6190
  year: 2016
  ident: 70791_CR33
  publication-title: Fresenius Environ. Bull.
– volume: 50
  start-page: 161
  year: 2000
  ident: 70791_CR41
  publication-title: Eur. J. Pharm. Biopharm.
  doi: 10.1016/S0939-6411(00)00087-4
– volume: 80
  start-page: 99
  year: 2000
  ident: 70791_CR73
  publication-title: Lab. Investig.
  doi: 10.1038/labinvest.3780013
– volume: 6
  start-page: 32
  year: 2001
  ident: 70791_CR69
  publication-title: Oncologist
  doi: 10.1634/theoncologist.6-suppl_5-32
– volume: 39
  start-page: 1783
  year: 2013
  ident: 70791_CR57
  publication-title: Drug Dev. Ind. Pharm.
  doi: 10.3109/03639045.2012.737331
– volume: 46
  start-page: 682
  year: 2020
  ident: 70791_CR19
  publication-title: Drug Dev. Ind. Pharm.
  doi: 10.1080/03639045.2020.1755304
– volume: 136
  start-page: 2
  year: 2009
  ident: 70791_CR15
  publication-title: J. Controlled Release
  doi: 10.1016/j.jconrel.2008.12.018
– volume: 12
  start-page: 2682
  year: 2020
  ident: 70791_CR4
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12092682
– volume: 91
  start-page: 3527
  year: 1998
  ident: 70791_CR72
  publication-title: Blood J. Am. Soc. Hematol.
– volume: 261
  start-page: 85
  year: 2014
  ident: 70791_CR52
  publication-title: Neuroscience
  doi: 10.1016/j.neuroscience.2013.12.027
– volume: 64
  year: 2021
  ident: 70791_CR60
  publication-title: J. Drug Deliv. Sci. Technol.
  doi: 10.1016/j.jddst.2021.102580
– volume: 13
  start-page: 7280
  year: 2007
  ident: 70791_CR3
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-07-2141
– volume: 23
  start-page: 1064
  year: 2020
  ident: 70791_CR28
  publication-title: Comb. Chem. High Throughput Screen
  doi: 10.2174/1386207323666200325155020
– volume: 10
  start-page: 17
  year: 2015
  ident: 70791_CR40
  publication-title: Res. Pharm. Sci.
– volume: 274
  start-page: 31047
  year: 1999
  ident: 70791_CR71
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.274.43.31047
– volume: 79
  start-page: 49
  year: 2017
  ident: 70791_CR32
  publication-title: Indian J. Pharm. Sci.
  doi: 10.4172/pharmaceutical-sciences.1000200
– ident: 70791_CR56
  doi: 10.3390/sci1020048
– volume: 49
  start-page: 4777
  year: 2022
  ident: 70791_CR39
  publication-title: Mol. Biol. Rep.
  doi: 10.1007/s11033-022-07329-w
– volume: 28
  start-page: 922
  year: 2014
  ident: 70791_CR48
  publication-title: J. Biomater. Appl.
  doi: 10.1177/0885328213486705
– volume: 18
  start-page: 1298
  year: 2013
  ident: 70791_CR63
  publication-title: J. Biomol. Screen
  doi: 10.1177/1087057113499405
– ident: 70791_CR54
  doi: 10.1007/s11033-021-06928-3
– volume: 10
  start-page: 1671
  year: 2010
  ident: 70791_CR64
  publication-title: Lab. Chip
  doi: 10.1039/c000022a
– ident: 70791_CR30
  doi: 10.1371/journal.pone.0260633
– volume: 19
  start-page: 1801
  year: 2018
  ident: 70791_CR11
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms19061801
– ident: 70791_CR55
  doi: 10.1155/2022/8082608
– volume: 32
  year: 2021
  ident: 70791_CR5
  publication-title: Nanotechnology
  doi: 10.1088/1361-6528/ac1098
– ident: 70791_CR62
  doi: 10.1038/nmeth.f.263
– volume: 67
  start-page: 379
  year: 2015
  ident: 70791_CR35
  publication-title: Cytotechnology
  doi: 10.1007/s10616-014-9692-5
– ident: 70791_CR27
  doi: 10.35333/jrp.2020.115
– volume: 38
  start-page: 87
  year: 2016
  ident: 70791_CR37
  publication-title: Immunopharmacol. Immunotoxicol.
  doi: 10.3109/08923973.2015.1122616
– volume: 118
  year: 2021
  ident: 70791_CR65
  publication-title: Proc. Natl. Acad. Sci.
  doi: 10.1073/pnas.2023829118
– volume: 23
  start-page: 897
  year: 2019
  ident: 70791_CR43
  publication-title: J. Res. Pharm.
– volume: 141
  start-page: 451
  year: 2019
  ident: 70791_CR29
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2019.01.013
– volume: 16
  start-page: 266
  year: 2021
  ident: 70791_CR46
  publication-title: Nat. Nanotechnol.
  doi: 10.1038/s41565-021-00858-8
– ident: 70791_CR36
SSID ssj0000529419
Score 2.4735992
Snippet Recent advancements in cancer therapy have led to the development of novel nanoparticle-based drug delivery systems aimed at enhancing the efficacy of...
Abstract Recent advancements in cancer therapy have led to the development of novel nanoparticle-based drug delivery systems aimed at enhancing the efficacy of...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 19837
SubjectTerms 631/67/1059/153
692/4028/67/2328
Angiogenesis
Angiogenesis Inhibitors - chemistry
Angiogenesis Inhibitors - pharmacology
Anti-angiogenesis
Antiangiogenic agents
Antineoplastic drugs
Aprepitant
Aprepitant - pharmacology
Cancer therapies
Cell migration
Cell Movement - drug effects
Cell Survival - drug effects
Cell viability
Chemotherapy
Cytotoxicity
Drug Carriers - chemistry
Drug delivery
Drug delivery systems
Endothelial cells
Fluorescence microscopy
Gene expression
Human Umbilical Vein Endothelial Cells - drug effects
Humanities and Social Sciences
Humans
HUVEC
Internalization
M2c
multidisciplinary
Nanoparticles
Nanoparticles - chemistry
Particle Size
Polylactic Acid-Polyglycolic Acid Copolymer - chemistry
Polylactide-co-glycolide
Science
Science (multidisciplinary)
THP-1
Umbilical vein
Vascular Endothelial Growth Factor A - metabolism
Vascular endothelial growth factor receptors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fi9QwEA5yIPgi_rZ6SgTfNFzatGnyqHLHIeiLCvcW0mTiFfbS43ZX2P_eSdJdb_354mublvDNTPOlmfmGkJcgvZYYZUx1CnCDwnWKOc76brChhjAEn2qHP3yUp1_a92fd2bVWXyknrMgDF-CORGubXuKmQCHz7TxYrWQqHdKua4JtMjXiml_bTBVV70a3tZ6rZLhQR0tcqVI1WdOyJApXs83eSpQF-3_HMn9NlvzpxDQvRCd3yO2ZQdI3ZeZ3yQ2I98jN0lNyc59cHMfzfKpPEbOR2fh1nNBJRkfn1A06BWovryC1C4krtpisx8HRRtw-z1lydIw0N--j64uUPIt2pN8AL0L0qWJrgU5L0y__5QPy6eT487tTNvdUYK5r6xUDkL1twQ615ANSOXA-AIcBiZtwvbI-BCSQ0AfVeYfRrgflhAUfhPTBiofkIE4RHhOaBI6Dxu8dvqgVwetGcQeIuQR8DFxF6i26xs1y46nrxcLkY2-hTLGIQYuYbBGzqcir3TOXRWzjr6PfJqPtRiah7HwB3cfMgJl_uU9FDrcmN3P0Lo3gSNIajfSpIi92tzHuErI2wrQuY1Rim7wij4qH7GYiNMKiGl0Rtec7e1PdvxPH86ztXSe5SOSQFXm9dbMf8_ozFk_-BxZPya0mxQfHb2d_SA5WV2t4hpRrNTzP0fUdMx4pOg
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection (ProQuest)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Jb9QwFLagCIkLYm9KQUbiBlazxz4hQK0qJLgA0twix35uI02dYZZK8-95z_GkGpZeEzty3uL32W9j7C3UVtWoZUJWEvCAkirSuVQ0VaddBq5zlnKHv36rz3-WX2bVLF64rWJY5W5PDBu1HQzdkZ8UKRrOXKFJ-7D4JahrFHlXYwuNu-xehkiEWjc0s2a6YyEvVpmpmCuTFvJkhfaKcsryUlBpuExs9-xRKNv_L6z5d8jkH37TYI7OHrGHEUfyjyPjH7M74J-w-2Nnye1TdnXqL4NvnyPleqH9RT-gqPSGxwAOPjiuF0ugpiF-LeaDtjjYa4-H6Bgrx3vPQws_vrmiEFrkJr8GfAjeUt7WHEWX08X_6hn7fnb64_O5iJ0VhKnKbC0A6kaXoLusTjsEdGCsgxQ6hG-FaaS2ziGMhMbJyhrUedVJU2iwrqit08VzduAHD4eMU5ljp3DXww-VhbMql6kBpHkNOA1MwrIddVsTi45T74t5G5zfhWxHjrTIkTZwpN0m7N00ZzGW3Lh19Cdi2jSSymWHB8Pyoo0Ea4tS502NJ0uJx6fKglaypvwzZarc6Vwn7HjH8jbq8Kq9kbiEvZleo_YRZbWHYTOOkYQ504S9GCVkWkmhkCwyVwmTe7Kzt9T9N76_DBW-MyoaiUgyYe93Ynazrv_T4uj233jJHuQk-Snujc0xO1gvN_AKIdW6ex305jekFiEW
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature HAS Fully OA
  dbid: AAJSJ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEB7SDYVeSt9xmhYVemtNbcsP6bgtCWGhvaSF3IwsjRLDRg77KOy_z0h-lG3TQq_2yIh5SJ-smW8A3mNpZElRFotCIB1QEuljLomrolE2RdtY42uHv34rz3_ki8vi8gCysRYmJO0HSsuwTI_ZYZ_WtNH4YrAsjz2nWxrvHsChqGj5ncHhfL64WEx_VvzdVZ7KoUIm4eKewXu7UCDrvw9h_pko-dttadiEzp7A4wE9snk_36dwgO4ZPOz7Se6ew82puw43-oz01cbKXbUdOUir2ZC2wTrL1O0KfasQt4mXnTIk7JSjo_OgA9Y6Fhr3se2NT5wlG7KfSA_RGV-ttSSHZf53__oFXJydfv9yHg_9FGJd5OkmRiwrlaNq0jJpCMahNhYTbAi0cV0JZawl8IiVFYXRFOmyEZorNJaXxir-Emauc3gEzJMbW0lrHX0o59bITCQaSecl0jDUEaSjdms9UI37jhfLOlx5c1H3FqnJInWwSL2L4MM05rYn2vin9GdvtEnSk2SHB93qqh4UVvNcZVVJ50lBh6bCoJKi9FVnUheZVZmK4GQ0eT1E7rrmCQG0TBJ0iuDd9JpizmtWOey2vYzwSDOJ4FXvIdNMuCS1iExGIPZ8Z2-q-29cex14vVNPFUn4MYKPo5v9mtffdXH8f-Kv4VHmIyGhFbI6gdlmtcU3BKw2zdshku4A5sog3Q
  priority: 102
  providerName: Springer Nature
Title Enhanced anti-angiogenic effects of aprepitant-loaded nanoparticles in human umbilical vein endothelial cells
URI https://link.springer.com/article/10.1038/s41598-024-70791-y
https://www.ncbi.nlm.nih.gov/pubmed/39191829
https://www.proquest.com/docview/3097629007
https://www.proquest.com/docview/3097851430
https://pubmed.ncbi.nlm.nih.gov/PMC11349893
https://doaj.org/article/34a27699889745dea986ce599c52fa2a
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ba9swFD70wmAvY_d564IGe9u8-W7pYYw0pJTAylhXyJuRraPWkMpdLqX59zuS7Yxs2WBPAVk24lykTznnfAfgLWZKZORlPk850gUlENbnAj9PS6lD1KVWtnb4y1l2epFMpul0D_p2R50AFzuvdraf1MV89uHux_ozOfyntmScf1zQIWQLxaLEt3xvob_eh0MXL7KpfB3cb7m-I5G4Xh-WhN0nMBF1dTS7P7N1VjlK_1049M90yt9iqu6oOnkIDzqMyYatUTyCPTSP4V7bdXL9BK7H5srF_RlJtfaluawbMqO6Yl1yB2s0kzdztA1FzNKfNVLRZCMNXbC7PDpWG-ba-7HVtU2vJU2zW6RBNMrWdM3IrJkNCiyewvnJ-Pvo1O-6LvhVmoRLHzHLZYKyDLOgJLCHldIYYEnQLq5yLpXWBDEx1zxVFe0HouRVLFHpOFNaxs_gwDQGXwCzFMha0I5IH0pirUTEgwpJ_hnSa1h5EPbSLaqOkNz2xZgVLjAe86LVSEEaKZxGirUH7zbv3LR0HP-cfWyVtplpqbTdQDO_LDqBFXEiozyjWyenq1WqUAqe2do0UaWRlpH04KhXedGbZxEHBOMiQQDLgzebx-SZVrLSYLNq53CLRwMPnrcWsllJLEgsPBIe8C3b2Vrq9hNTXzn279ASShLK9OB9b2a_1vV3Wbz8L8m9gvuRdYSAttH8CA6W8xW-JvS1LAewn0_zARwOh5PzCf0ej8--fqPRUTYauH80Bs7pfgIWnTBc
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3ZbtNAcFRSIXhB3BgKLBI8gVXfXj9UiEKqlLYRgiL1CWvtnW0jpeuQA5R_4-OY8ZEqHH3rq71rreeenQvgJSY6S4jLXBlLJAfFy5jnPDeNC2V8NIXRXDt8NEwGX6OPJ_HJBvzqamE4rbKTibWg1lXJd-TboUeKM8hIpb2dfHd5ahRHV7sRGqodraB36hZjbWHHAS5_kgs329n_QPh-FQR7_eP3A7edMuCWceTPXcQkVRGqwk-8gowbLLVBDwsyZcIylUobQyYVpkbGuiT6zwpZhgq1CRNtVEhfvQabEV-f9GBztz_89Hl1x8NRtMjP2lodL5TbM9KXXNMWRC63pvPd5Zo-rMcG_MvW_Ttl84-4ba0O927DrdaOFe8awrsDG2jvwvVmsuXyHpz37VmdWyAIcyNX2dNRRaQ6KkWbQCIqI9Rkijy0xM7dcaU0LbbKkhPf5uqJkRX1CEGxOOcUXqIm8QPpIVrNdWNjYh3BgYfZffhyBTB_AD1bWXwEgtssm4ykLn0oCo3OAumVSDBPkLZh6YDfQTcv26bnPHtjnNfB91DmDUZywkheYyRfOvB6tWfStPy4dPUuI221ktt11w-q6WneAiwPIxWkCXm2kty3WKPKZML1b1kZB0YFyoGtDuV5K0Nm-QXFO_Bi9Zq4nyGrLFaLZo1km9dz4GFDIauThBmBRQaZA3KNdtaOuv7Gjs7qDuM-N60kS9aBNx2ZXZzr_7B4fPlvPIcbg-Ojw_xwf3jwBG4GzAUeyel0C3rz6QKfknk3L561XCTg29Wy7W-R_2aA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3JbtQw1CqtQFwqdgIFjAQniJo9zqFClM6opTCqWKSeajnxczvS1JnOApo_5LN4L3GmGpbeeo0dy3n7y9sYewWZLjLkMl-kAtBBCQriucDP01KZEExpNNUOfx5k-9-Tj8fp8Rr71dXCUFplJxMbQa3riv6Rb8cBKs6ooLI349Iijvb678YXPk2QokhrN05DuTELeqdpN-aKPA5h8RPduenOwR7i_nUU9XvfPuz7buKAX6VJOPMBslwloMowC0o0dKDSBgIo0ayJq1wobQyaV5AbkeoKeaEoRRUr0CbOtFExnnqDbeSo89EN3NjtDY6-LP_3UEQtCQtXtxPEYnuKupPq26LEpzZ1ob9Y0Y3NCIF_2b1_p2_-EcNtVGP_Dtt0Ni1_3xLhXbYG9h672U65XNxn5z171uQZcMTi0Ff2dFgj2Q4r7pJJeG24Gk-ABpjYmT-qlcbNVll06F3eHh9a3owT5PNzSudFyuI_AB-C1VRDNkI24hSEmD5gX68B5g_Zuq0tPGacWi6bAiUwHpTERheRCCpAmGeAr0HlsbCDrqxcA3SawzGSTSA-FrLFiESMyAYjcuGxN8t3xm37jyt37xLSljupdXfzoJ6cSgcwGScqyjP0cgW6cqkGVYiMauGKKo2MipTHtjqUSydPpvKS-j32crmMkoAgqyzU83aPIPs38NijlkKWN4kLBIuICo-JFdpZuerqih2eNd3GQ2pgiVatx952ZHZ5r__D4snVn_GC3UL2lZ8OBodP2e2ImCBAkZ1vsfXZZA7P0NKblc8dE3F2cr1c-xtMaWrE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Enhanced+anti-angiogenic+effects+of+aprepitant-loaded+nanoparticles+in+human+umbilical+vein+endothelial+cells&rft.jtitle=Scientific+reports&rft.au=Kaya-Tilki%2C+Elif&rft.au=%C3%96zt%C3%BCrk%2C+Ahmet+Alper&rft.au=Eng%C3%BCr-%C3%96zt%C3%BCrk%2C+Selin&rft.au=Dikmen%2C+Miri%C5%9F&rft.date=2024-08-27&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=14&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-024-70791-y&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41598_024_70791_y
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon